Posted on: September 7th 2026
Pharmacovigilance has always been a race against time. Today, the FDA’s Adverse Event Reporting System (FAERS) holds more than 24 million safety reports and receives over 2 million new reports each year.
Add scientific literature, electronic health records (EHRs), real-world data, and digital channels, and identifying meaningful safety signals becomes more challenging than ever.
Artificial intelligence has already improved safety operations by automating repetitive tasks and accelerating data analysis. AI agents take it further by continuously monitoring diverse data sources, connecting fragmented information, and surfacing potential safety signals for expert review.
The Need for AI Agents in Pharmacovigilance
For years, the biggest challenge in drug safety was collecting adverse event data. That is no longer the problem.
The real challenge is keeping up with it.
Safety teams must monitor adverse event reports alongside scientific literature, EHRs, real-world evidence, patient support programs, and digital channels. While new data sources improve visibility, they also increase the risk of critical signals remaining hidden across disconnected systems.
Traditional operating models were never built for this environment. They depend on sequential reviews, predefined workflows, and significant manual effort. As data grows faster than teams can evaluate it, speed becomes a scientific capability rather than just an operational metric.
The question is no longer whether organizations need more safety data. It is whether they can identify the right signal before the next one arrives.
“The future of drug safety will not belong to those who collect the most data. It will belong to those who recognize risk before it disappears into the noise.”
Understanding AI Agents in Pharmacovigilance
For years, AI in drug safety was expected to speed up individual tasks. AI agents redefine that expectation. Their value lies not in completing a single task, but in coordinating an entire safety workflow.
This is the shift. Traditional automation executes predefined rules. Generative AI responds to prompts. Autonomous AI agents work toward defined objectives.
They gather information across systems, reason through multiple steps, determine the next best action, and escalate complex decisions to human experts while operating within established guardrails.
In pharmacovigilance, this enables safety teams to move beyond isolated automation toward continuous, connected decision support.
The opportunity extends beyond efficiency. McKinsey’s analysis of 270 workflows, 1,200 tasks, and 180 job families found that 75% to 85% of workflows contain activities that AI agents can augment or automate.
The goal is not to replace scientific judgment. It is to give experts more time to apply it where it matters most.
“The next phase of AI will not be defined by better answers. It will be defined by better decisions.”
Applications of AI Agents Across the Pharmacovigilance Lifecycle
AI agents create value across the pharmacovigilance lifecycle by orchestrating data, decisions, and actions across connected safety workflows.
Adverse Event Case Intake and Processing
Automatically capture, classify, prioritize, and enrich adverse event reports from multiple sources, reducing manual effort while improving case quality.
Straive’s AI-powered pharmacovigilance workflows process large volumes of adverse event data to enable faster, more accurate safety detection.
Scientific Literature Monitoring
Continuously scan global scientific publications to identify potential safety signals, ensuring faster detection and regulatory compliance.
| Straive’s AI-enabled literature search and knowledge extraction capabilities help teams surface relevant evidence from large volumes of biomedical content. |
EHR and Real-World Evidence Analysis
Analyze electronic health records and real-world evidence to uncover emerging risk patterns and strengthen signal validation with broader clinical context.
| Straive’s domain-led RWE capabilities help curate and analyze diverse real-world data to generate decision-ready clinical insights. |
Clinical Trial Data Analysis
Analyze clinical trial data to identify potential safety risks, uncover emerging patterns, and support more informed pharmacovigilance decisions.
| Straive combines AI-driven clinical data analysis and validation to improve data quality and surface actionable insights across complex trial datasets. |
Signal Detection and Regulatory Reporting
Correlate evidence across data sources, prioritize potential safety signals, and generate audit-ready documentation for faster regulatory reporting and compliance.
| Straive’s AI-driven safety workflows detect, validate, and structure safety signals into traceable, regulator-ready outputs. |
Benefits of Agentic Pharmacovigilance
The conversation is no longer about automating pharmacovigilance. It is about expanding human capacity. As AI agents take on repetitive, data-intensive tasks, safety professionals can focus on the scientific decisions that shape patient outcomes.
Accelerated Safety Operations
Automate routine activities across case processing, literature monitoring, and signal management, enabling faster and more consistent safety workflows.
Greater Scientific Capacity
Reduce administrative burden so safety teams can dedicate more time to signal assessment, risk evaluation, and regulatory decision-making.
Improved Patient Safety
Enable earlier identification, assessment, and prioritization of emerging safety risks, supporting timely interventions while reducing regulatory and patient safety risks.
Scalable Pharmacovigilance
Adapt to growing volumes of safety data without proportionally increasing operational effort, creating a resilient model for future drug safety operations.
Challenges and Considerations for Adoption
The technology is moving faster than the governance around it.
Data quality remains the foundation. AI agents can only reason from the evidence they receive. Incomplete or inconsistent safety data can compromise downstream decisions.
Validation becomes more complex. AI agents adapt, interact, and make multi-step decisions, making continuous validation as important as initial deployment.
Governance cannot be an afterthought. Clear accountability, auditability, and explainability are essential to keep AI-assisted decisions transparent and inspection-ready.
Human oversight remains non-negotiable. AI agents can accelerate signal assessment, but scientific judgment, benefit-risk evaluation, and regulatory accountability remain the responsibility of pharmacovigilance professionals.
| Challenge | What Straive Offers |
| Data quality remains the foundation | Clinical data quality, curation, and AI-driven validation to improve the accuracy, completeness, and reliability of complex clinical datasets. |
| Validation becomes more complex | Multi-layer AI validation and explainable safety workflows to validate adverse-event identification and make outputs more reliable and traceable. |
| Governance cannot be an afterthought | Data governance, quality controls, and regulatory-ready frameworks to strengthen accountability, consistency, traceability, and compliance across data workflows. |
| Human oversight remains non-negotiable | Human-in-the-loop safety workflows that combine AI-driven processing with expert review for complex pharmacovigilance decisions. |
The Future of AI Agents in Pharmacovigilance
The future of pharmacovigilance will not be defined by autonomous AI. It will be defined by intelligent collaboration between AI agents and safety professionals.
The next challenge is not adoption. It is trust.
Success will depend on trusted data, robust validation, regulatory alignment, and human oversight at every stage of the safety lifecycle.
The bigger shift is already underway.
Pharmacovigilance is moving from periodic case reviews to continuous safety intelligence, where AI agents monitor emerging evidence, support scientific decision-making, and help identify potential risks earlier.
“The organizations that lead the next generation of pharmacovigilance will not be those with the most AI. They will be the ones that combine intelligent agents with trusted human judgment.”
Santosh Shevade is a Principal Data Consultant at Gramener – A Straive Company. With deep expertise in healthcare strategy, digital health, and clinical development and operations, he has supported nearly 50 clinical development programs across all clinical phases. His experience spans advanced analytics solution design for pharmaceutical companies, mHealth implementation, and AI applications in healthcare. Previously at Novartis and Johnson & Johnson, Santosh led global clinical development teams and streamlined data review processes for major regulatory submissions. A certified MBTI trainer and leadership coach, he serves as visiting faculty at ISB Hyderabad and Welingkar Institute, focusing on healthcare technology innovation and biopharma strategy.
